From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer - Summary - MDSpire
Advertisement
From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer
To summarize recent progress in bladder cancer therapy and translational research, focusing on the biological basis and evolution of gemcitabine resistance, emphasizing its clinical significance.
Key Findings:
Gemcitabine remains a central treatment for bladder cancer despite resistance issues.
Resistance can be categorized into three stages: early, intermediate, and late adaptive resistance.
Most mechanistic findings related to gemcitabine resistance are still at the preclinical or retrospective validation stage.
Interpretation:
Understanding gemcitabine resistance is crucial for advancing research; however, specific claims about treatment sequencing and precision management should be removed unless directly supported.
Limitations:
No markers currently approved for routine clinical use.
Most findings are not yet clinically validated.
Conclusion:
A roadmap is provided for advancing mechanistic discoveries into patient care, specifically addressing the need for clinically useful guidance based on current findings.
